Deutsche Bank Initiates PTC Therapeutics At Buy

Analysts at Deutsche Bank initiated coverage on shares of PTC Therapeutics

with a Buy rating. The target price for PTC Therapeutics is set to $75. PTC Therapeutics shares have surged 57.46% over the past 52 weeks, while the S&P 500 index has gained 16.96% in the same period. PTC Therapeutics' shares fell 3.37% to close at $32.72 on Friday.